Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Editorial

Melanoma: the role of surgery in the era of new therapies

Authors: Nicola Mozzillo, Paolo A Ascierto

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Excerpt

Stage IV melanoma has historically been associated with poor outcomes, with a typical one-year survival rate of around 25% [1]. In particular, patients who develop distant metastases have a poor prognosis. Treatment of these patients involves systemic medical therapy, radiotherapy and surgery. …
Literature
1.
Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008, 26: 527-534. 10.1200/JCO.2007.12.7837.CrossRefPubMed
2.
Reeves E, Bridge P, Appleyard RM: The current role of systemic therapy in the management of malignant melanoma of the skin: a literature review. J Radiother Pract. 2005, 4: 161-175. 10.1017/S1460396905000221.CrossRef
3.
Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR: Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007, 33: 665-680. 10.1016/j.ctrv.2007.06.004.CrossRefPubMed
4.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056/NEJMoa1003466.PubMedCentralCrossRefPubMed
5.
Robert C, Thomas L, Bondarenko I, O’Day S, JW MD, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011, 364: 2517-2526. 10.1056/NEJMoa1104621.CrossRefPubMed
6.
Ascierto PA, Marincola FM, Ribas A: Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med. 2011, 9: 196-10.1186/1479-5876-9-196.PubMedCentralCrossRefPubMed
7.
Ascierto PA, Marincola FM: What have we learned from cancer immunotherapy in the last 3 years?. J Transl Med. 2014, 12: 141-10.1186/1479-5876-12-141.PubMedCentralCrossRefPubMed
8.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N: The role of BRAF V600 mutation in melanoma. J Transl Med. 2012, 10: 85-10.1186/1479-5876-10-85.PubMedCentralCrossRefPubMed
9.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364: 2507-2516. 10.1056/NEJMoa1103782.PubMedCentralCrossRefPubMed
10.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O’Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014, 15: 323-332. 10.1016/S1470-2045(14)70012-9.PubMedCentralCrossRefPubMed
11.
Ascierto PA, Streicher HZ, Sznol M: Melanoma: a model for testing new agents in combination therapies. J Transl Med. 2010, 8: 38-10.1186/1479-5876-8-38.PubMedCentralCrossRefPubMed
12.
Hoshimoto S, Faries MB, Morton DL, Shingai T, KUO C, Wang HJ, Elashoff R, Mozzillo N, Kelley MC, Thompson JF, Lee JE, Hoon DS: Assessment of prognostic circulating tumor cells in a phase III Trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012, 255: 357-362. 10.1097/SLA.0b013e3182380f56.PubMedCentralCrossRefPubMed
13.
Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra MJ, Roses DF, Sondar VK, Reintgen DS, Rasmai-Sabet M, Karavousis CP, Coventry BJ, Kraybill WG, Smithers BM, Elashoff R, Stern SL, Cohran AJ, Faries MB, Morton DL: Metastasectomy for distant metastatic melanoma: analysis of data from the first MSLT (MSLT I). Ann Surg Oncol. 2012, 19: 2547-2555. 10.1245/s10434-012-2398-z.PubMedCentralCrossRefPubMed
14.
Meyer T, Merkel S, Goehl J, Hohenberger W: Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000, 89: 1983-1991. 10.1002/1097-0142(20001101)89:9<1983::AID-CNCR15>3.3.CO;2-J.CrossRefPubMed
15.
Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995, 110: 119-128. 10.1016/S0022-5223(05)80017-0.CrossRefPubMed
16.
Ollila DW, Stern SL, Morton DL: Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol. 1998, 69: 206-211. 10.1002/(SICI)1096-9098(199812)69:4<206::AID-JSO3>3.0.CO;2-N.CrossRefPubMed
17.
Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK: A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011, 117: 4740-06. 10.1002/cncr.26111.PubMedCentralCrossRefPubMed
18.
Amaravadi RK, Kim KB, Flaherty KT, Chapman P, Puzanov I, Sosman J, Ribas A, Lee R, Nolop K, McArthur GA: Prolonged responses to vemurafenib in patients with BRAF V600E mutant melanoma with low tumor burden at baseline. Pigment Cell Res. 2011, 24 (3): 1024-
19.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU: Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014, 15: 436-444. 10.1016/S1470-2045(14)70051-8.CrossRefPubMed
20.
Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I: Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol. 2011, 29 (8519): 530s-
21.
Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA: Immunological and biological Changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014, 63: 675-683. 10.1007/s00262-014-1545-8.CrossRefPubMed
Metadata
Title
Melanoma: the role of surgery in the era of new therapies
Authors
Nicola Mozzillo
Paolo A Ascierto
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-195

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue

Research

Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor

Research

Targeted genomic capture and massively parallel sequencing to identify novel variants causing Chinese hereditary hearing loss

Methodology

Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection

Research

Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission

Review

The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science

Research

Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits